Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide

Sarah M Michienzi, Mikayla Johnson, Thomas D Chiampas, Eric Wenzler, Rodrigo M Burgos, Renata O Smith, Melissa E Badowski

Article Type

Original Research

Published

The goal of this retrospective analysis is to assess changes in virological suppression, immunological status, renal function, weight and body mass index (BMI) amongst people living with HIV who switched from a tenofovir disoproxil fumarate-based to a tenofovir alafenamide-based regimen.

Read more

Potential risk of drug–drug interactions with hormonal contraceptives and antiretrovirals: prevalence in women living with HIV

Milena M Murray PharmD, MSc, Ashley Jensen PharmD, Thomas Cieslik PharmD Candidate, Susan E Cohn MD, MPH

Article Type

Original Research

Published

The objectives of this study were to assess antiretroviral therapy and hormonal contraceptive use among women living with HIV and quantify the frequency of potential drug–drug interactions between antiretroviral therapy and hormonal contraceptives.

Read more

HIV, drugs and the kidney

Nicola Wearne MBChB, FCP, MMed, Bianca Davidson MBChB, FCP, MMed, Marc Blockman MBChB, BPharm, PG Dip Int Res Ethics, MMed, Annoesjka Swart BScPharm, Erika SW Jones MBBCh, FCP, PhD

Article Type

Review

Published

This review discusses antiretroviral therapy and its nephrotoxic effects, including drug–drug interactions. It aims to guide the clinician on dose adjustment in the setting of renal impairment and dialysis, for the commonly used drugs in patients with HIV.

Read more

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

Hanh Thi Pham PhD, Meng A Xiao BSc, Miguel AV Principe BSc, Alexander Wong MD, Thibault Mesplède PhD

Article Type

Review

Published

This review summarizes chemical, pharmacological, and clinical information about doravirine with an emphasis on drug resistance. The efficacy results from an early phase clinical trial evaluating doravirine in combination with islatravir are also provided.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.